

Alignments between cortical neurochemical systems, proteinopathy and neurophysiological alterations along the Alzheimer's disease continuum

Alex I. Wiesman^{1*}, Jonathan Gallego-Rudolf^{1,2}, Sylvia Villeneuve^{1,2}, Sylvain Baillet^{1†}, Tony W. Wilson^{3,4†}, and the PREVENT-AD Research Group[†]

¹ Montreal Neurological Institute, McGill University, Montreal, Canada

² Douglas Mental Health University Institute, Montreal, Quebec, Canada

³ Institute for Human Neuroscience, Boys Town National Research Hospital, Omaha, NE, USA

⁴ Department of Pharmacology & Neuroscience, Creighton University, Omaha, NE, USA

* Corresponding author

† Authors contributed equally to this report

Correspondence:

Alex I. Wiesman, PhD
McConnell Brain Imaging Centre
Montreal Neurological Institute
McGill University, Montreal QC
aiwiesman@gmail.com

Running title: Cortical neurochemical alignments in AD

‡Data used in preparation of this article were obtained from the Pre-symptomatic Evaluation of Novel or Experimental Treatments for Alzheimer's Disease (PREVENT-AD) program (<https://douglas.research.mcgill.ca/stop-ad-centre>). A complete listing of PREVENT-AD Research Group can be found in the PREVENT-AD database: [https://preventad.loris.ca/acknowledgements/acknowledgements.php?date=\[2024-04-02\]](https://preventad.loris.ca/acknowledgements/acknowledgements.php?date=[2024-04-02]). The investigators of the PREVENT-AD program contributed to the design and implementation of PREVENT-AD and/or provided data but did not participate in analysis or writing of this report.

1 Abstract

2 Two neuropathological hallmarks of Alzheimer's disease (AD) are the accumulation of amyloid- β ($A\beta$)
3 proteins and alterations in cortical neurophysiological signaling. Despite parallel research indicating
4 disruption of multiple neurotransmitter systems in AD, it has been unclear whether these two phenomena
5 are related to the neurochemical organization of the cortex. We leveraged task-free
6 magnetoencephalography and positron emission tomography, with a cortical atlas of 19 neurotransmitters
7 to study the alignment and interactions between alterations of neurophysiological signaling, $A\beta$ deposition,
8 and the neurochemical gradients of the human cortex. In patients with amnesic mild cognitive impairment
9 ($N = 18$) and probable AD ($N = 20$), we found that changes in rhythmic, but not arrhythmic, cortical
10 neurophysiological signaling relative to healthy controls ($N = 20$) are topographically aligned with
11 cholinergic, serotonergic, and dopaminergic neurochemical systems. These neuro-physio-chemical
12 alignments are related to the severity of cognitive and behavioral impairments. We also found that cortical
13 $A\beta$ plaques are preferentially deposited along neurochemical boundaries, and mediate how beta-band
14 rhythmic cortical activity maps align with muscarinic acetylcholine receptors. Finally, we show in an
15 independent dataset that many of these alignments manifest in the asymptomatic stages of cortical $A\beta$
16 accumulation ($N = 33$; $N = 71$ healthy controls), particularly the $A\beta$ -neurochemical alignments (57.1%) and
17 neuro-physio-chemical alignments in the alpha frequency band (62.5%). Overall, the present study
18 demonstrates that the expression of pathology in pre-clinical and clinical AD aligns topographically with the
19 cortical distribution of chemical neuromodulator systems, scaling with clinical severity and with
20 implications for potential pharmacotherapeutic pathways.

21 Keywords

22 Alzheimer's disease continuum; mild cognitive impairment; amyloid- β ; magnetoencephalography;
23 neurotransmitter systems; spectral parameterization; rhythmic neurophysiological signaling; neural
24 oscillations

1 Introduction

2 Alzheimer's disease (AD) is marked by cortical accumulations of cytotoxic proteins including amyloid- β ($A\beta$)
3 and hyper-phosphorylated tau, which are associated with alterations of neurophysiological activity¹⁻⁴.
4 These alterations are expressed across multiple frequency bands^{1,2,5-11}, and are associated with the severity
5 of hallmark impairments in memory, attention and executive function^{1,5,12,13}. Unlike superficially similar
6 relationships observed in Parkinson's disease¹⁴, pathological alterations in AD are predominantly *rhythmic*
7 in nature¹⁵. Rhythmic neurophysiology can be modulated non-invasively via frequency-targeted
8 neuromodulation¹⁶⁻²¹, making aberrant neurophysiological oscillations a promising target for emerging
9 therapeutics. Despite these advances, the mechanistic bases of neurophysiological alterations in AD are
10 understudied in human participants.

11 Decades of research have also indicated that a subset of neurotransmitter systems are degraded as patients
12 progress along the AD continuum. In particular, cholinergic and glutamatergic signaling are dysfunctional
13 in AD with relevance for cognitive impairments²²⁻²⁵. Both of these neurotransmitter systems also represent
14 pharmacological targets in AD, via acetylcholinesterase inhibitors and memantine, respectively^{22,25}. More
15 recently, losses of function in dopaminergic and serotonergic pathways have also been linked to psychiatric
16 and behavioral symptoms in AD²⁶⁻²⁹. Due to their shared associations with cognitive and behavioral
17 impairments, it is possible that the aforementioned neurophysiological alterations and accumulations of
18 proteinopathy seen in patients with AD are influenced by these neurochemical systems.

19 Recent research has indicated that the topographical alignment of altered neurophysiological activity and
20 neurochemical systems are clinically-informative in Parkinson's disease³⁰. However, similar relationships
21 between neurochemistry and clinically-relevant alterations in macro-scale neurophysiology have not been
22 characterized in patients with AD. In the current study, we examine the alignment of AD-related
23 neurophysiological alterations and proteinopathy with the principal neurochemical systems of the cortex,
24 as well as the associations between these alignments and the hallmark cognitive and behavioral symptoms
25 of the disease. From the above review of the field, we hypothesized that rhythmic neurophysiological
26 alterations in AD would align preferentially with cortical cholinergic, glutamatergic, dopaminergic and
27 serotonergic systems, due to their shared involvement in the disease process. We expected that the extent
28 of these alignments would relate to the severity of cognitive and behavioral symptoms. We also predicted
29 that these alignments would be mediated by the regional deposition of $A\beta$ plaques, indicating a stronger
30 cytotoxic effect on neurophysiology in brain regions with specific neurochemical profiles. Finally, we
31 hypothesized that these alignments would be detectable in asymptomatic older adults with high levels of
32 cortical $A\beta$ deposition, possibly indicating promising novel targets for early-stage disease monitoring and
33 intervention.

1 Results

2 Topographies of neurochemical gradients and neurophysiological alterations & amyloid- β deposition in patients with aMCI and AD




Figure 1. Topographies of normative neurochemical gradients and neurophysiological alterations in patients with aMCI and AD. Normative gradients of cortical neurotransmitter system density were derived from 19 normative neurotransmitter atlases using principal component analysis. The first four principal components (pc1 to pc4) explained more than 80% of the variance across atlases (all p 's < .001; 1,000 permutations). Heatmaps in (a) show the respective loadings (i.e., eigenvectors) for each neurochemical gradient across the 19 atlases. Positive and negative loadings are colored red and blue, respectively, and labels in black indicate systems that significantly contribute to each gradient (p 's < .05; 1,000 permutations). The spatial topographies of these neurochemical gradients are shown as cortical maps in (b), with warm colors indicating regions with high densities of positively-loaded neurochemical systems and cool colors indicating regions with high densities of negatively-loaded systems. The cortical maps shown in (c) indicate the group-average spatial topographies of alterations in rhythmic neurophysiology in patients with aMCI and AD from the DMAP cohort, per each canonical frequency band (i.e., δ : 2 – 4 Hz; θ : 5 – 7 Hz; α : 8 – 12 Hz; β : 15 – 29 Hz). Note that these topographies represent rhythmic neurophysiological measures that have been standardized (i.e., z-scored) to the comparable data from the healthy control participants. Warm and cool colors indicate increases and decreases in rhythmic activity relative to healthy levels, respectively.

1 To account for the complex co-localization and co-release of neurotransmitter systems in the human
2 cortex, we data-reduced the 19 neurotransmitter system atlases into four neurochemical gradients using
3 principal component analysis (1,000 permutations; accounting for 81.7% of total spatial variance; all p 's <
4 .001). These gradients have been discussed extensively in previous work^{30,66} and are shown in Figures 1a
5 and 1b. Briefly, the first gradient (pc1; eigenvalue = 6.13; 32.3% of spatial variance) exhibited positive
6 loadings from most modeled receptors and transporters; the second gradient (pc2; eigenvalue = 4.79;
7 25.2% of spatial variance) contrasted cortical regions rich in norepinephrine, GABA, acetylcholine, and 5-
8 HT1b/5-HT6 serotonin systems from those with higher densities of dopamine, mu-opioid, cannabinoid, and
9 other serotonergic (5-HT1a, 5-HT4, and 5-HTT) systems; the third gradient (pc3; eigenvalue = 2.56; 13.5%
10 of spatial variance) described a spatial pattern of regions rich in GABAergic, serotonergic (5-HT2a and 5-
11 HTT), and glutamatergic (NMDA) systems versus those with lesser mu-opioid and cannabinoid systems; and
12 the fourth gradient (pc4; eigenvalue = 2.04; 10.7% of spatial variance) mapped onto regions with low
13 serotonergic (5-HT2a and 5-HT4) and acetylcholinergic (M1) receptor densities.

14 Cortical maps representing the mean region-wise alterations in rhythmic and arrhythmic neurophysiology
15 across the DMAP patients with aMCI and AD are shown in Figures 1c and S1, respectively. These patients
16 exhibited increases in low-frequency (i.e., delta- and theta-band) rhythms relative to healthy levels in
17 prefrontal and parieto-occipital regions, alongside pronounced decreases in high-frequency (i.e., alpha- and
18 beta-band) neurophysiological rhythms strongest in frontal and temporal areas. Beta rhythms were also
19 selectively increased in parietal and prefrontal regions.

20 Patients with aMCI and AD exhibited increased aperiodic offsets and steeper aperiodic slopes in prefrontal
21 and parieto-occipital regions relative to healthy participants, indicating increased arrhythmic signaling,
22 particularly in slower frequencies (Figure S1).

23 The deposition of A β plaques also exhibited a stereotyped topography in patients with aMCI and AD: SUVRs
24 were highest in prefrontal and parieto-temporal cortices bilaterally (Figure S1).


25 Neurophysiological alterations in patients with aMCI and AD align with 26 neurochemical systems

27 We tested the alignment of neurophysiological alterations in patients with aMCI and AD with the four
28 neurochemical gradients using nested linear models (Figure 2; see *Methods: Modeling of Spatial*
29 *Colocalization*).

30 Generally, AD-related alterations in rhythmic, but not arrhythmic, neurophysiological activity were aligned
31 with neurochemical systems. Disease-related increases in slower delta and theta rhythms were stronger in
32 cortical regions with low density of dopaminergic, serotonergic, and mu-opioid receptors/transporters,
33 while disease-related decreases in faster alpha and beta activity were weaker in these regions. Alpha and
34 beta rhythmic decreases were also stronger in brain regions with high densities of glutamatergic receptors,
35 and increases in beta rhythms favored areas rich in muscarinic cholinergic systems.

36 Rhythmic activity in the slower delta ($t = 4.34$, $p_{\text{FDR}} < .001$) and theta ($t = 3.16$, $p_{\text{FDR}} = .005$) bands was aligned
37 with the second principal neurochemical gradient (Figure 2a-b). For delta alterations, the neurotransmitter
38 systems that contributed most to this colocalization were dopaminergic (DAT: $t = -4.25$, $p_{\text{FDR}} < .001$; D2: $t =$
39 -3.80 , $p_{\text{FDR}} < .001$), serotonergic (5-HT1a: $t = -4.53$, $p_{\text{FDR}} < .001$; 5-HT4: $t = -4.23$, $p_{\text{FDR}} < .001$), and mu-opioid
40 (MOR: $t = -4.36$, $p_{\text{FDR}} < .001$). For theta rhythmic alterations, noradrenergic (NET: $t = -3.81$, $p_{\text{FDR}} = .002$),

a | neuro-physio-chemical alignments in patients with aMCI and AD



b | neuro-physio-chemical alignments associated with AD clinical symptoms




Figure 2. Neurophysiological alterations in patients with aMCI and AD align to neurochemical systems with relevance for clinical symptoms. The heatmap in (a) indicates the strength of the alignments between band-limited alterations in rhythmic neurophysiology (y-axis) and the normative neurochemical gradients (x-axis) from Figure 1. Colors indicate the t-values of these relationships, with asterisks indicating statistical significance after correcting for multiple comparisons. Line plots in (a) show the participant-level simple slopes representing two of these alignments, with the remaining alignments displayed in Figure S2. Overlaid cortical maps indicate the dot product of the relevant neurophysiological alterations and neurochemical gradient densities per region, with warm and cool colors indicating positive and negative agreement, respectively, between the two measures. Representative topographies of delta rhythmic alterations from patients with high and low alignment to the second neurochemical gradient are shown in Figure S3. Scatterplots in (b) indicate the moderations of neurochemical-neurophysiological alignments from (a) by cross-sectional clinical symptom severity, with the strength of alignment shown on the x-axis and the clinical symptom score shown on the y-axis. Inlaid neurotransmitter receptor/transporter abbreviations indicate the respective atlases that replicate the relevant moderation effect in post-hoc testing, with the color and saturation of each label indicating the sign of the corresponding loading onto the neurochemical gradient. For all plots, the color of the lines/points indicates whether patients were in the amnesic mild cognitive impairment or probable Alzheimer’s disease clinical subgroup. *** $p_{FDR} < .005$, ** $p_{FDR} < .01$, * $p_{FDR} < .05$.

- 1 serotonergic (5-HT1a: $t = -3.41$, $p_{FDR} = .004$; 5-HT6: $t = -2.96$, $p_{FDR} = .012$), dopaminergic (D2: $t = -2.75$, $p_{FDR} = .018$), and GABAergic (GABAA: $t = -2.47$, $p_{FDR} = .032$) systems were aligned.
- 2
- 3 We found that AD-related alterations in rhythmic alpha ($t = -2.53$, $p_{FDR} = .026$) and beta ($t = -4.99$, $p_{FDR} < .001$) activity colocalized negatively with the first neurochemical gradient (Figure 2a-b), with strongest
- 4 alignments to dopaminergic (DAT-beta: $t = -6.28$, $p_{FDR} < .001$; DAT-alpha: $t = -4.82$, $p_{FDR} < .001$; D1-beta: $t = -5.70$, $p_{FDR} < .001$; D1-alpha: $t = -2.93$, $p_{FDR} = .011$; D2-beta: $t = -5.44$, $p_{FDR} < .001$; D2-alpha: $t = -4.89$, $p_{FDR} < .001$).
- 5
- 6

1 .001), mu-opioid (MOR-beta: $t = -5.72$, $p_{\text{FDR}} < .001$; MOR-alpha: $t = -2.89$, $p_{\text{FDR}} = .011$), and glutamatergic
2 (NMDA-beta: $t = -4.99$, $p_{\text{FDR}} < .001$; NMDA-alpha: $t = -3.32$, $p_{\text{FDR}} = .004$) systems. These alterations in fast
3 alpha and beta rhythms were also aligned positively with the second neurochemical gradient, again with
4 strong contributions from dopaminergic and mu-opioid systems, and additional contributions from
5 serotonin systems (5-HT1a-beta: $t = -7.17$, $p_{\text{FDR}} < .001$; 5-HT1a-alpha: $t = -5.43$, $p_{\text{FDR}} < .001$; 5-HTT-beta: $t =$
6 -5.60 , $p_{\text{FDR}} < .001$; 5-HTT-alpha: $t = -3.16$, $p_{\text{FDR}} = .004$; 5-HT4-alpha: $t = -3.79$, $p_{\text{FDR}} < .001$). Finally, alterations
7 in beta rhythms were aligned negatively with the fourth neurochemical gradient ($t = -2.65$, $p_{\text{FDR}} = .021$),
8 with contributions from serotonergic (5-HT4: $t = -4.98$, $p_{\text{FDR}} < .001$) and cholinergic (M1: $t = 3.94$, $p_{\text{FDR}} <$
9 $.001$) systems.

10 None of these alignments were moderated by clinical subgroup (i.e., aMCI versus AD). The alignments to
11 the first neurochemical gradient remained significant when an atlas of synaptic density (i.e., glycoprotein)
12 was included as a nuisance covariate, indicating they are not attributable to regional variations in non-
13 specific receptor densities. No significant alignments to the third neurochemical gradient were observed.
14 Arrhythmic neurophysiological alterations were not aligned to any of the four neurochemical gradients (all
15 $p_{\text{FDR}}'s > .150$). These arrhythmic models remained non-significant when the region-wise aperiodic model
16 fits (standardized to those of the healthy control data) were included as a nuisance covariate.

17 Neurophysiological-neurochemical alignments are associated with 18 cognitive and behavioral symptoms

19 We examined whether the strength of these neurochemical alignments was associated with cognitive and
20 behavioral symptoms in patients with aMCI and AD (Figure 2c).

21 We found moderations of the slow-rhythmic alignments to the second neurochemical gradient by
22 behavioral symptoms (i.e., QDRS behavioral score; delta-pc2: $t = -2.99$, $p_{\text{FDR}} = .020$; theta-pc2: $t = -2.49$, p_{FDR}
23 $= .044$), such that greater delta and theta rhythmic increases in brain regions rich in dopaminergic and
24 serotonergic systems were related to worse behavioral symptoms.

25 We also found that the alignment between beta rhythmic alterations and the fourth neurochemical
26 gradient was moderated by attention function ($t = -2.93$, $p_{\text{FDR}} = .024$), such that increased beta rhythmic
27 activity, relative to healthy levels, in brain regions rich in muscarinic acetylcholine receptor M1 was related
28 to worse cognitive abilities.

29 Deposition of amyloid- β in patients with aMCI and AD aligns with 30 neurochemical systems

31 We next tested whether the deposition of A β plaques in the DMAP participants occurs preferentially in
32 brain regions with specific neurochemical profiles. We found alignment between the topographies of A β
33 deposition and the second ($t = 11.84$, $p_{\text{FDR}} < .001$), third ($t = -24.21$, $p_{\text{FDR}} < .001$), and fourth ($t = -16.22$, p_{FDR}
34 $< .001$) neurochemical gradients (Figure 3). The alignment of A β with the second neurochemical gradient
35 was moderated by clinical subgroup, such that patients with a diagnosis of probable AD exhibited stronger
36 alignments than those with aMCI ($t = 2.49$, $p_{\text{FDR}} = .038$).

37 These relationships were such that A β tended to accumulate in brain regions rich in cholinergic ($\alpha 4\beta 2$: $t =$
38 20.22 , $p_{\text{FDR}} < .001$; M1: $t = 8.52$, $p_{\text{FDR}} < .001$), cannabinoid (CB1: $t = 9.23$, $p_{\text{FDR}} < .001$), mu-opioid (MOR: $t =$




Figure 3. Cortical deposition of amyloid- β in patients with aMCI and AD aligns with neurochemical systems. Cortical maps in (a) show the mean topography of amyloid- β deposition (in standardized uptake value ratios; derived from ^{18}F florbetapir positron emission tomography) across patients with aMCI and AD from the DMAP cohort. The heatmap in (b) indicates the strength of the alignments between cortical deposition of amyloid- β (x-axis) and the normative neurochemical gradients (y-axis) in these patients. Colors indicate the t-values of these relationships, with asterisks indicating statistical significance after correcting for multiple comparisons. Line plots in (b) show the participant-level simple slopes representing the alignments from (a), with line color indicating whether patients were in the amnestic mild cognitive impairment or probable Alzheimer's disease clinical subgroup. Cortical maps below are the dot product of the amyloid- β values and neurochemical gradient densities per region, with warm and cool colors indicating positive and negative agreement, respectively, between the two measures. Representative topographies of amyloid- β deposition from patients with high and low alignment to the fourth neurochemical gradient are shown in Figure S4. *** $p_{FDR} < .005$.

1 8.40, $p_{FDR} < .001$), noradrenergic (NET: $t = 2.71$, $p_{FDR} = .007$), and two of the serotonergic (5-HT6: $t = 4.39$,
 2 $p_{FDR} < .001$; 5-HT1b: $t = 9.92$, $p_{FDR} < .001$) systems, and conversely spared brain regions rich in dopaminergic
 3 (D2: $t = -7.10$, $p_{FDR} < .001$; DAT: $t = -19.24$, $p_{FDR} < .001$), glutamatergic (NMDA: $t = -12.55$, $p_{FDR} < .001$),
 4 GABAergic (GABAa: $t = -8.18$, $p_{FDR} < .001$), and other serotonergic (5-HT1a: $t = -14.72$, $p_{FDR} < .001$; 5-HT4: t
 5 $= -9.64$, $p_{FDR} < .001$; 5-HTT: $t = -22.14$, $p_{FDR} < .001$) systems.

6 Amyloid- β deposition mediates the alignment of beta rhythmic 7 alterations with cholinergic systems in patients with aMCI and AD

8 Next, we examined whether any of the alignments of rhythmic neurophysiological alterations with
 9 neurochemical systems were mediated by the deposition of A β in the DMAP participants. Of the seven
 10 alignments, only one exhibited evidence of a potential mediation effect: the relationship between beta
 11 rhythmic alterations and the fourth neurochemical gradient ($t = -2.65$, $p = .008$) became non-significant (t
 12 $= -1.84$, $p = .067$) when participant-level maps of A β deposition were added as a covariate. Causal mediation
 13 analysis confirmed that this was a full mediation (Figure 4), as indicated by a significant indirect effect
 14 (average causal mediation effect: -0.029 , $p = .018$) and a non-significant direct effect (average direct effect:

| A β mediates the cholinergic alignment of β rhythmic alterations in patients with aMCI and AD




Figure 4. Amyloid- β deposition mediates the neurochemical alignment of beta rhythmic alterations in patients with aMCI and AD. Cortical maps indicate the topographies of mean beta rhythmic alterations (bottom left), mean amyloid- β deposition (top), and the fourth normative neurochemical gradient (bottom right). Linear mixed-effects model statistics (t -values) above the paths between these variables indicate their alignment, with asterisks representing statistical significance. The t -value below the path on the bottom indicates the residual alignment of beta rhythmic alterations with the fourth neurochemical gradient when amyloid- β deposition is included in the model. The average causal mediation effect (ACME) is shown at the top, confirming an indirect effect. This indirect effect was also significant when the fourth neurochemical gradient was replaced with the atlas of muscarinic acetylcholine M1 receptor densities. *** $p_{\text{FDR}} < .005$, ** $p_{\text{FDR}} < .01$, * $p_{\text{FDR}} < .05$.

1 -0.024, $p = .098$). This indirect effect was also significant when specifically considering alignments to
 2 muscarinic acetylcholine M1 receptors (average causal mediation effect: 0.01, $p = .020$).

3 Neurophysiological and proteinopathic neurochemical alignments are 4 detectable in the asymptomatic stages of A β deposition

5 Finally, we investigated whether neurochemical alignments observed in the later stages of the AD
 6 continuum are also detectable in an independent sample of asymptomatic older adults expressing high
 7 cortical deposition of A β from the PREVENT-AD cohort (Figure 5a). Despite differences in MEG
 8 instrumentation, data collection paradigm & site, data processing, and the A β PET tracer used (see
 9 *Methods: Positron Emission Tomography data collection & processing* and *Magnetoencephalography data*
 10 *collection & processing*), we found that many of the alignments identified in the DMAP participants were
 11 detectable in asymptomatic participants with high A β from PREVENT-AD (Figures 5b and 5c). Alignments
 12 between beta rhythmic alterations and M1 receptors ($t = 5.42$, $p_{\text{FDR}} < .001$), and between alpha rhythmic
 13 alterations and dopaminergic (DAT: $t = -9.06$, $p_{\text{FDR}} < .001$; D1: $t = -6.91$, $p_{\text{FDR}} < .001$), glutamatergic (NMDA:
 14 $t = -8.81$, $p_{\text{FDR}} < .001$), and serotonergic (5-HT1a: $t = -2.77$, $p_{\text{FDR}} = .009$; 5-HTT: $t = -3.50$, $p_{\text{FDR}} < .001$) systems
 15 were replicated in the asymptomatic stages of A β deposition.




Figure 5. Alignments between normative neurochemical gradients, neurophysiological alterations, and proteinopathy are detectable in the asymptomatic stages of A β deposition. The rhythmic neurophysiological measures from the high-A β individuals (N = 33) from the PREVENT-AD cohort were standardized to the comparable data from the low-A β individuals (N = 71) to generate the neurophysiological alteration maps shown in (a). The heatmap in (b) indicates the replication in PREVENT-AD high A β participants of neurochemical-neurophysiological alignments that were observed in patients with aMCI and AD from the DMAP cohort, with band-limited alterations in rhythmic neurophysiology on the y-axis and normative neurochemical atlases on the x-axis. The colors of the squares indicate the t-values of these alignments, with asterisks indicating statistical significance after correcting for multiple comparisons. Grey squares were not significant in the DMAP cohort, and were not examined. Brain maps in (c) indicate the mean topography of A β deposition (in standardized uptake value ratios; derived from 18 F NAV4694 positron emission tomography) across asymptomatic adults with high A β deposition from the PREVENT-AD cohort. The heatmap in (c) indicates the replication in PREVENT-AD high A β participants of neurochemical-A β alignments that were observed in patients with aMCI and AD from the DMAP cohort. Similar to (b), colors indicate the t-values of these relationships, with asterisks indicating statistical significance after correcting for multiple comparisons. *** $p_{FDR} < .005$, ** $p_{FDR} < .01$, * $p_{FDR} < .05$.

- 1 Alignments between regional A β deposition and cholinergic (α 4 β 2: $t = 12.92$, $p_{\text{FDR}} < .001$; M1: $t = 2.58$, p_{FDR}
- 2 = .012), mu-opioid (MOR: $t = 6.24$, $p_{\text{FDR}} < .001$), noradrenergic (NET: $t = 9.48$, $p_{\text{FDR}} < .001$), and serotonergic
- 3 (5-HT6: $t = 11.90$, $p_{\text{FDR}} < .001$; 5-HT1b: $t = 11.03$, $p_{\text{FDR}} < .001$; 5-HT4: $t = -7.62$, $p_{\text{FDR}} < .001$; 5-HTT: $t = -5.39$,
- 4 $p_{\text{FDR}} < .001$) systems were also replicated in asymptomatic individuals with high A β (Figure 5c).
- 5 We did not find any moderations of the detected neurochemical-neurophysiological alignments by
- 6 cognitive abilities in these asymptomatic participants (all p 's $> .05$).

1 Discussion

2 Despite evidence of dysfunction across multiple neurotransmitter systems in AD, how this dysfunction
3 shapes cortical neurophysiology has remained unclear. Here, we find that rhythmic, but not arrhythmic,
4 alterations in cortical neurophysiology in patients with aMCI and AD are aligned with the spatial
5 topographies of cholinergic, serotonergic, and dopaminergic systems. The strength of these alignments is
6 associated with the severity of clinical impairments. Marked beta-band increases in muscarinic
7 acetylcholine receptor M1-dense regions are associated with worse attention & executive functions, and
8 stronger delta- and theta-band increases in brain regions rich in dopaminergic, serotonergic, and nicotinic
9 acetylcholinergic systems are related to worse behavioral symptoms. These neurochemical systems also
10 shape the topography of A β deposition in patients with aMCI and AD, which accounts for the alignment of
11 beta-rhythmic alterations with cholinergic M1 receptors.

12 Muscarinic cholinergic M1 receptors emerged in our findings as a particularly important system for shaping
13 the topography of neurophysiological changes and proteinopathy in AD. Increases in beta-rhythmic activity
14 were found to be strongest in M1-dense cortical regions in our study, and this alignment was accounted
15 for by individual variations in the deposition of A β plaques. M1 receptors are G-protein coupled cholinergic
16 receptors with the highest density in prefrontal and temporal cortices^{71,72}. They promote increased signal-
17 to-noise and synaptic plasticity⁷². M1 receptor dysfunction is tightly linked to AD pathology: A β interferes
18 with M1 signaling²³ and M1 receptor activity enhances non-amyloidogenic processing of amyloid precursor
19 protein⁷³⁻⁷⁵.

20 Beta-frequency alterations have also been extensively reported in patients with AD^{5,11,76} and associated
21 with healthy muscarinic cholinergic neuromodulation⁷⁷⁻⁷⁹. We found that cholinergic-beta alignments are
22 related to the severity of attention & executive function impairments in patients with aMCI and AD.
23 Reduced function of muscarinic acetylcholine receptors has been tied to attention & executive function
24 impairments in healthy subjects⁸⁰⁻⁸² and AD⁸³ due to accelerated cytotoxicity. We found that M1 receptor-
25 beta alignments are also expressed in asymptomatic older adults with high levels of cortical A β deposition.
26 This finding is promising for novel approaches to pre-clinical pharmacotherapies and disease monitoring.
27 These results unify disparate lines of research, highlighting the association between A β deposition, M1
28 receptor dysfunction, and changes in beta rhythmic neurophysiology in AD, with relevance for cognitive
29 symptoms.

30 We also found that increased low-frequency (i.e., delta and theta) rhythmic activity in patients with aMCI
31 and AD is expressed along the topographies of dopaminergic and serotonergic cortical systems, and that
32 such alignments are related to the severity of behavioral symptoms. Previous studies reported that
33 dopaminergic and serotonergic functions are related to behavioral and psychiatric issues in patients on the
34 AD continuum²⁶⁻²⁹. However, the neurophysiological bases of behavioral and psychiatric symptoms in AD
35 have, so far, been understudied. Limited previous findings suggest that low-frequency neurophysiological
36 alterations are related to such symptoms^{5,84-87}, which our present results confirm. We emphasize, however,
37 that such alignment of low-frequency activity with dopaminergic/serotonergic cortical systems were not
38 present in our data from participants in the asymptomatic stage of A β deposition. We may hypothesize
39 that low-frequency neurophysiological activity may not be aligned with these systems in the pre-clinical
40 stage because behavioral symptoms tend to appear later than cognitive impairments in the course of
41 AD^{88,89}.

1 We also report that the deposition of A β proteinopathy aligns with the distinct cortical topographies of
2 neurochemical systems in patients with aMCI and AD. Specifically, we found that amyloid plaques are
3 deposited preferentially in regions rich in cholinergic, noradrenergic, serotonergic, mu-opioid, and
4 cannabinoid neurotransmitter systems. Previous work has also linked acetylcholine, serotonin, and
5 norepinephrine dysfunction to A β ⁹⁰. In our study, we found that only the alignment to cholinergic receptors
6 is related to alterations in neurophysiology. This observation is compatible with the known early
7 susceptibility of cholinergic receptors to A β cytotoxicity⁹¹. The topographical alignment between A β
8 deposits and cholinergic, noradrenergic, mu-opioid, and serotonin systems also replicated in our data from
9 asymptomatic participants with early A β deposition. Despite these intriguing findings, future investigations
10 using the larger sample of clinical, MRI, and PET data (including both A β and tau maps) from the Alzheimer's
11 Disease Neuroimaging Initiative⁹² are a clear next step for this line of research.

12 Using normative neurotransmitter atlas data to contextualize cortical alterations in clinical populations has
13 inherent limitations. Foremost of these limitations is the use of PET data collected from healthy participants
14 to contextualize alterations seen in a patient group known to exhibit changes in the same neurotransmitter
15 systems. However, we argue that this aspect only constrains the discussion of our findings, not their
16 robustness. Despite reductions in the local densities of several neurochemical systems in AD, it is unlikely
17 that their respective macro-scale cortical topographies are entirely altered in patients. For this reason, the
18 discussion of our present observations is limited in *how* these systems causally affect neurophysiological
19 alterations and proteinopathy (e.g., whether these changes result from the degeneration of the system or
20 from its compensatory over-activation). Yet, our data can valuably determine *whether* these systems are
21 associated with the pathological processes of the disease. In some cases, this limitation can be overcome
22 by the inclusion of measures known to indicate pathology, such as A β deposition. Nevertheless, the
23 *neuromaps* neurotransmitter atlases are currently the only option for performing neurochemical
24 contextualization studies across multiple neurochemical systems. Future research into inter-participant
25 cholinergic, dopaminergic, and serotonergic variability in AD will help fill the remaining knowledge gaps.

26 Collectively, the present data highlight that neurophysiological alterations and the deposition of harmful
27 proteins in AD co-localize with specific cortical neurochemical systems. These topographical alignments are
28 relevant for hallmark behavioral and cognitive symptoms of the disease, and can be detected even in the
29 asymptomatic stages of A β deposition. Looking forward, we anticipate that these findings will inspire
30 further research to validate the mechanistic pathways identified in AD between dopamine and serotonin
31 signaling, low-frequency rhythmic alterations, and behavioral symptoms; as well as between A β deposition,
32 muscarinic cholinergic signaling, beta-frequency rhythmic alterations, and cognitive impairments. More
33 detailed and sensitive analyses of the neurochemical alignments of AD A β and tau proteinopathies in
34 individual patients are also warranted.

1 Materials and Methods

2 Participants

3 Data were aggregated from two studies to examine the clinical (i.e., patients with amnesic mild cognitive
4 impairment [aMCI] and probable AD) and pre-clinical (i.e., asymptomatic older adults with high A β
5 deposition) stages of the AD continuum.

6 Patients with amnesic mild cognitive impairment and probable Alzheimer's disease

7 Data from patients with aMCI and probable AD were included via the Dynamic Mapping of Alzheimer's
8 disease Pathology (DMAP) study⁵. The Institutional Review Board at the University of Nebraska Medical
9 Center reviewed and approved this investigation, and all research protocols complied with the Declaration
10 of Helsinki. Written informed consent was obtained from each participant (as well as, for participants in
11 the patient group, from their spouse/child informant) following detailed description of the study. For
12 individuals with diminished capacity to make an informed decision regarding research participation,
13 educated assent was acquired from the participant, in addition to informed consent of their legally
14 authorized representative.

15 Forty-four participants were referred from a memory disorders clinic and screened for recruitment into the
16 aMCI/AD group. All such participants were determined as having either aMCI or mild probable AD by a
17 fellowship-trained neurologist using standard clinical criteria³¹. A positive whole-brain quantitative A β PET
18 scan was also required for inclusion into the final aMCI/AD patient participant sample (see *Florbetapir*^{18F}
19 *Positron Emission Tomography* below). One participant was excluded from this group due to a major
20 incidental MRI finding that was likely to impact cognitive function, and another disenrolled due to COVID-
21 19 related health concerns. Four additional participants were excluded after they were indicated as being
22 A β -negative based on their A β PET scan. After exclusions, 38 A β -positive participants remained for inclusion
23 into the aMCI/AD patient group (aMCI: N = 18, probable AD: N = 20).

24 For comparison and standardization of the aMCI/AD patient group relative to an analogous group of healthy
25 control participants, 20 additional older adults who reported no subjective cognitive concerns were
26 screened for inclusion into the study. Nineteen of these participants were confirmed to be A β -negative by
27 means of a PET scan within the past five years, while one participant received no such test, but performed
28 exceedingly well on all neuropsychological tests. The 19 A β -negative participants were recruited based on
29 their previous enrollment in an unrelated clinical trial of an anti-amyloid drug in cognitively healthy older
30 adults, where they were discovered to be A β -negative during the screening process and excluded from
31 participation. These participants did not exhibit any cognitive disturbances on detailed neuropsychological
32 assessments.

33 Exclusionary criteria for both groups included any medical illness affecting CNS function, diagnosis of any
34 neurological disorder (other than Alzheimer's disease), history of head trauma, moderate or severe
35 depression (Geriatric Depression Scale \geq 10), and current substance abuse. Demographic factors were
36 matched across the HC and aMCI/AD participant groups (highest level of education: $t = 1.44$, $p = .156$; sex:
37 $\chi^2 = 0.84$, $p = .360$) with the exception of age ($t = 2.02$, $p = .048$), such that patients with aMCI/AD were
38 younger than those in the HC group. Note that age was included (alongside highest level of education) as a
39 nuisance covariate in all statistical analysis.

1 Asymptomatic older adults with high A β

2 Data from asymptomatic older adults with elevated familial risk of sporadic AD were included via the Pre-
3 symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD)
4 cohort³². The Institutional Review Board at McGill University reviewed and approved this investigation, and
5 all research protocols complied with the Declaration of Helsinki. Written informed consent was obtained
6 from each participant following detailed description of the study. Normal cognition at time of enrollment
7 was assessed using the Montreal Cognitive Assessment (MoCA) and the Clinical Dementia Rating scale
8 (CDR). Individuals with MoCA scores < 27 or CDR scores > 0 were further examined by a neuropsychologist
9 from the PREVENT-AD group to verify their cognitive status. Individuals with neurological or psychiatric
10 illness affecting CNS function were excluded. From the subsample of 124 participants who underwent both
11 A β PET and resting-state MEG, 20 were excluded due to issues with data quality ($N_{\text{MEG}} = 19$, $N_{\text{PET}} = 1$). The
12 remaining 104 participants were then divided into high- and low-A β individuals based on an established
13 sensitive threshold (see *Materials and Methods: Positron Emission Tomography*; high-A β : $N = 33$; low-A β :
14 $N = 71$). The asymptomatic low- and high-A β groups did not significantly differ in age ($t = -0.36$, $p = .721$),
15 sex ($\chi^2 = 1.37$, $p = .241$), or highest level of education ($t = 0.94$, $p = .352$). These demographics were also
16 matched between the high-A β group from PREVENT-AD and the patients with aMCI/AD from DMAP on age
17 ($t = -1.06$, $p = .293$) and education ($t = -1.34$, $p = .185$), but not sex ($\chi^2 = 7.40$, $p = .007$).

18 Demographics for each group from the DMAP and PREVENT-AD studies, as well as comparisons between
19 groups, can be found in Table 1.

20 Neuropsychological & clinical testing

21 Participants in the DMAP study completed a series of neuropsychological tests focusing on five cognitive
22 domains: attention & executive function, memory, learning, verbal function, and processing speed. Raw
23 scores for each participant were converted to demographically adjusted z-scores based on published
24 normative data³³⁻³⁶ and averaged within each functional domain to create composite domain z-scores.
25 Details on the neuropsychological tests administered, as well as on the statistical independence of the
26 domain z-scores can be found in previous publications^{5,37,38}. In collaboration with a spouse or child
27 informant for patients with aMCI and AD, instrumental activities of daily living (iADLs) were measured using
28 the Functional Activities Questionnaire (FAQ)³⁹, and dementia severity and behavioral symptoms were
29 measured using the Quick Dementia Rating System (QDRS)⁴⁰. General cognitive status was measured using
30 the MoCA⁴¹ and the Mini-mental State Examination (MMSE)⁴².

31 Participants in the PREVENT-AD study underwent cognitive assessment using the Repeatable Battery for
32 the Assessment of Neuropsychological Status (RBANS)⁴³, which yields scaled scores subdivided into five
33 cognitive domains comprising immediate and delayed memory, attention, visuospatial constructional
34 abilities, and language.

35 We focused our analyses on the cognitive domains most commonly associated with AD: attention &
36 executive function and memory⁴⁴. We also examined associations with IADLs and behavioral symptoms
37 (measured via the behavioral symptom subscale of the QDRS, in the DMAP study only).

1 Positron emission tomography data collection & processing

2 In the DMAP study, combined PET/CT data using ^{18}F -florbetapir (Amyvid™, Eli Lilly) were collected following
3 procedures described by the Society of Nuclear Medicine and Molecular Imaging (3D acquisition; single
4 intravenous slow-bolus < 10 mL; dose = 370 MBq; waiting period = 30-50 min; acquisition = 10 min)⁴⁵ using
5 a GE Discovery MI digital PET/CT scanner (Waukesha, WI). PET images were attenuation-corrected using
6 the CT data, and reconstructed in MIMNeuro (slice thickness = 2 mm)⁴⁶, converted to voxel-wise
7 standardized uptake values based on body weight (SUVbw), and then normalized into MNI space. Each scan
8 was read by a fellowship-trained neuroradiologist, who was blinded to their group assignment, and
9 assessed as being “A β -positive” or “A β -negative” using established clinical criteria⁴⁶. Those who were A β -
10 negative were excluded from the patient group at this point. Images were then normalized to the crus of
11 the cerebellum (SUIT template)⁴⁷ to generate voxel-wise maps of SUV ratios⁴⁸, and back-transformed into
12 native space using each individual’s FreeSurfer-processed T1 MRI data. The PET data overlapping with each
13 individual’s cortical gray-matter ribbon was projected onto a tessellated *FSAverage* template surface using
14 `mri_vol2surf` (maximum value; projection fraction = 1; steps of 2)⁴⁹, and spatially smoothed (FWHM:
15 8mm)^{50,51}. These data were then averaged within each region of the Desikan-Killiany atlas⁵².

16 In the PREVENT-AD study, PET imaging data were collected using a Siemens HRRT head-only, high-
17 resolution PET camera³². A β scans were performed 40 to 70 minutes after injection of $\approx 6\text{mCi}$ of ^{18}F -
18 NAV4694 (Navidea Biopharmaceuticals, Dublin, OH). Images were reconstructed using a 3D OP OSEM (10
19 iterations, 16 subsets) algorithm, and were decay and motion corrected. Scatter correction was performed
20 using a 3D scatter estimation method⁵³. PET images were preprocessed using an in-house pipeline from
21 the Villeneuve lab (<https://github.com/villeneuvelab/vlpp>). Briefly, the 4D image files (6 frames of 5
22 minutes for NAV) were realigned, averaged, and registered to their corresponding structural MRI.
23 Standardized uptake value ratio (SUVR) maps were generated by using the cerebellum gray matter as a
24 reference region for A β scans. The resulting SUVR values were averaged across each parcel from the
25 Desikan-Killiany atlas⁵² and then again over a meta-ROI of early A β -accumulating cortical regions⁵⁴ and
26 converted them to centiloid scale following established procedures and formulas^{55,56}. Participants were
27 divided into high- and low-A β groups based on a centiloid threshold of 18 (SUVR = 1.249), which is optimal
28 for predicting future cognitive decline in asymptomatic individuals^{57,58}.

29 Magnetoencephalography data collection & processing

30 In the DMAP study, participants were seated in a nonmagnetic chair with their head positioned within the
31 MEG sensor array, and rested with their eyes closed for 8 minutes⁵⁹. Recordings were conducted in a one-
32 layer magnetically-shielded room with active shielding engaged for environmental noise compensation.
33 Neuromagnetic responses were sampled continuously at 1 kHz with an acquisition bandwidth of 0.1– 330
34 Hz using a 306-sensor Elekta/MEGIN MEG system (Helsinki, Finland) equipped with 204 planar
35 gradiometers and 102 magnetometers. Preceding MEG measurement, four head position indicator coils
36 were attached to the participant’s head and localized, together with the three fiducial points and about
37 100 scalp surface points, using a Fastrak 3-D digitizer (Polhemus Navigator Sciences, Colchester, VT, USA).
38 Each MEG dataset was individually corrected for head motion and subjected to noise reduction using the
39 signal space separation method with a temporal extension (correlation limit: .950; correlation window
40 duration: 6 seconds)⁶⁰. Only data from the gradiometers were used for analysis. Structural MRI data were

1 also collected for each participant, for co-registration of their MEG data (Siemens Prisma 3T; 64-channel
2 head coil; TR: 2.3 s; TE: 2.98 ms; flip angle: 9°; FOV: 256 mm; slice thickness: 1 mm; voxel size: 1 mm³).

3 In the PREVENT-AD study, at least two 5-minute runs (i.e., a total of 10 minutes)⁵⁹ of resting state, eyes
4 open MEG data were collected from the participants⁵⁹ as they fixated on a central crosshair displayed on a
5 screen. Data were collected using a 275-channel whole-head CTF system (Port Coquitlam, British Columbia,
6 Canada) at a sampling rate of 2400 Hz and with an antialiasing filter with a 600 Hz cut-off. Built-in third-
7 order gradient compensation was applied to attenuate environmental noise. About 100 scalp points were
8 localized in each participant with a Polhemus Fastrak device, including anatomical landmarks at the nasion
9 and the left and right preauricular points. Head movements during MEG data collection were monitored
10 with head position indicators attached to the participants' forehead and the left and right mastoids,
11 alongside reference signals for heartbeats and eye movements with concurrent electrocardiographic and
12 electrooculographic recordings. Structural MRI data were also collected for each participant, for co-
13 registration of their MEG data (Siemens TIM Trio 3T; 12- or 32-channel head coil; TR: 2.3 s; TE: 2.98 ms; flip
14 angle: 9°; FOV: 256x240x176 mm; slice thickness: 1 mm; voxel size: 1 mm³).

15 For both studies, triangulated cortical surfaces were derived from the T1 MRI data with *FreeSurfer*
16 *recon_all*⁴⁹ using default settings and imported into *Brainstorm*⁶¹. Using digitized points of the scalp and
17 fiducials, each participant's MEG data were co-registered with their own high-resolution structural T1-
18 weighted MRI data using an iterative closest-point rigid-body registration in *Brainstorm* and manually
19 corrected following visual inspection. Individual cortical surfaces were down-sampled to 15,000 vertices
20 for use in MEG source imaging.

21 *Brainstorm* was used for MEG data preprocessing and analysis and followed recommended good-practice
22 procedures⁶². After import into *Brainstorm*, MEG data were filtered (DMAP: bandpass = 1 - 200 Hz & notch
23 = [60, 120, 180] Hz; PREVENT-AD: high-pass = 0.3 Hz & notch = [60, 120, 180, 240, 300] Hz), and ocular and
24 cardiac artifacts were identified using an automated identification algorithm, supplemented by visual
25 inspection of their temporal and spatial topography. Signal-Space Projectors (SSPs) were generated for
26 each type of artifact, the temporal and spatial topography of these SSPs were reviewed, and those
27 accounting for ocular and cardiac components were removed from the gradiometer data. Artifact-reduced
28 MEG data were then arbitrarily epoched into non-overlapping blocks of 4 s and, in the DMAP study,
29 downsampled to 500 Hz. Epochs still containing major artifacts (e.g., SQUID jumps) were excluded within
30 each participant using the U of standardized thresholds median absolute deviations from the median
31 (DMAP: ± 2.5 MAD; PREVENT-AD: ± 3.0 MAD) for peak-to-peak signal amplitude and gradient. Empty-room
32 recordings of ≥ 2 min, collected around each individual scanning session, were processed using an identical
33 pipeline to the one described above (with the exception of the artifact SSP), to model the environmental
34 noise statistics for source analysis.

35 In both studies, MEG data were source imaged using an overlapping-spheres forward model. For the DMAP
36 study, a linearly constrained minimum variance beamformer implemented in *Brainstorm* was used to
37 spatially-filter the epoch-wise data with source orientations unconstrained to the cortical surface. In the
38 PREVENT-AD study, we estimated the imaging kernels using depth-weighted dynamic statistical parametric
39 mapping (dSPM) with cortical current flows oriented perpendicularly to the cortex⁶³. The source-level time
40 series data were then transformed into the frequency-domain using Welch's method (DMAP: window = 1s;
41 50% overlap; PREVENT-AD: window = 2s; 50% overlap) and parameterized using *specparam*⁶⁴ (*Brainstorm*
42 Matlab version; DMAP frequency range = 2 – 30 Hz; PREVENT-AD frequency range = 1 – 40 Hz; Gaussian

1 peak model; peak width limits = 0.5 – 12 Hz; maximum n peaks = 3; minimum peak height = 3 dB; proximity
2 threshold = 2 standard deviations of the largest peak; fixed aperiodic; no guess weight).

3 To represent the arrhythmic features of the neurophysiological power spectrum, the slope and offset of
4 the aperiodic model fit were extracted at each vertex. The rhythmic (i.e., aperiodic-corrected) spectra were
5 derived by subtracting the aperiodic spectra from the original PSDs. Arrhythmic and rhythmic
6 neurophysiological features were averaged over vertices within each region of the Desikan-Killiany atlas⁵².
7 Rhythmic spectral data were then averaged over canonical frequency bands (delta: 2–4 Hz; theta: 5–7 Hz;
8 alpha: 8–12 Hz; beta: 15–29 Hz). This procedure produced six maps of neurophysiological brain activity per
9 participant: one for rhythmic activity in each of the four canonical frequency bands, and one for each of
10 the broadband arrhythmic model features (i.e., aperiodic slope and offset).

11 Normative atlases of neurotransmitter system density

12 Similar to previous work³⁰, we used *neuromaps*⁶⁵ to obtain mean cortical distribution maps of 19 receptors
13 and transporters, following previously-established procedures⁶⁶ and parcellated the resulting topographies
14 according to the Desikan-Killiany atlas⁵². We obtained normative densities for dopamine (D1: 13 adults,
15 [11C]SCH23390 PET; D2: 92, [11C]FLB-457, DAT: 174, [123I]-FP-CIT), serotonin (5-HT1a: 36, [11C]WAY-
16 100635; 5-HT1b: 88, [11C]P943; 5-HT2a: 29, [11C]Cimbi-36; 5-HT4: 59, [11C]SB207145; 5-HT6: 30,
17 [11C]GSK215083; 5-HTT: 100, [11C]DASB), acetylcholine ($\alpha 4\beta 2$: 30, [18F]flubatine; M1: 24,
18 [11C]LSN3172176; VACHT: 30, [18F]FEOBV), GABA (GABAA: 16, [11C]flumazenil), glutamate (NMDA: 29,
19 [18F]GE-179; mGluR5: 123, [11C]ABP688), norepinephrine (NET: 77, [11C]MRB), histamine (H3: 8,
20 [11C]GSK189254), cannabinoids (CB1: 77, [11C]OMAR), and opioids (MOR: 204, [11C]Carfentanil). We
21 derived the principal patterns of spatial variance (i.e., gradients) across these 19 maps using principal
22 component analysis (PCA, with each map first scaled and centered), using the *prcomp* and *PCAtest*⁶⁷
23 functions in *R*⁶⁸. Permutation testing was used to determine statistically-significant principal components⁶⁷,
24 with *p*-values calculated by comparing the empirical eigenvalue of each component to a null distribution of
25 eigenvalues derived from 1,000 random permutations of the underlying data. We retained the principal
26 components with *p* < .05 for further analysis, as representative topographies of the principal normative
27 cortical neurochemical gradients of the human brain. To test the importance of synapse density, we also
28 retrieved the cortical atlas topography of synaptic vesicle glycoprotein 2A (76 adults, [11C]UCB-J) from
29 *neuromaps*.

30 Modeling of spatial colocalization

31 To quantify the topographies of neurophysiological alterations for each participant on the AD continuum
32 (i.e., patients with aMCI/AD from DMAP, asymptomatic adults with high A β from PREVENT-AD), the
33 neurophysiological features were z-scored with respect to the means and standard deviations of analogous
34 data from participants without high A β deposition (i.e., the healthy control group from DMAP, the low-A β
35 participants from PREVENT-AD).

36 We estimated the alignment of neurophysiological alterations and A β deposition with the *neuromaps*
37 principal gradients using linear mixed-effects modeling³⁰ via the *nlme* package in *R*. For each participant on
38 the AD continuum, this approach models a nested intercept and slope representing the linear relationship
39 between these region-wise cortical features and the selected *neuromaps* gradient, and thus exploits the
40 within-subject variability in the data that would be ignored by group-level colocalization analysis. These
41 models were computed with the following form: *neuromap pc* ~ *alterations + covariates*, *random* = (~1 +

1 alterations | *participant*). Significant relationships between neurochemical gradients and alterations were
2 displayed by plotting the nested simple slopes between these variables per participant.

3 We examined whether significant neurochemical alignments are moderated by cognitive function (i.e.,
4 attention & executive function, memory), IADLs (i.e., FAQ scores; available only in the DMAP study), and
5 behavioral symptoms (i.e., QDRS-Behavioral scores; available only in the DMAP study) by including these
6 variables as interaction terms in the linear mixed-effects models. The effects of significant continuous
7 moderators were visualized by extracting the nested model slope coefficients per participant and plotting
8 them against the moderator. We also tested significant alignments in the DMAP participants for
9 moderations by clinical subgroup (i.e., aMCI versus probable AD).

10 For each significant neurochemical alignment, as well as for significant moderations of these alignments,
11 we performed post-hoc testing to assess the specificity of the statistical effect to each neurotransmitter
12 system. This was done by regressing (i.e., using a comparable linear mixed-effects model) the relevant
13 alterations on each *neuromap* atlas that exhibited significant loadings onto the relevant neurochemical
14 gradient.

15 All models included age and highest level of education as cross-sectional nuisance covariates. We used the
16 Benjamini-Hochberg method to correct parametric tests for multiple comparisons across related
17 hypotheses, with a threshold for significance set to $p_{FDR} < .05$.

18 Initial step-wise linear mixed-effects models were used to identify potential mediation effects⁶⁹. Indirect
19 effects were then tested statistically via causal mediation analysis with quasi-Bayesian approximation using
20 the *mediation* package in *R*⁷⁰.

21 Data availability

22 Due to concerns over patient confidentiality the MEG and PET data from the DMAP study cannot be shared
23 on an open repository, but will be made available from the corresponding author upon reasonable request.

24 Some of the data from the PREVENT-AD study are publicly available (<https://openpreventad.loris.ca/>,
25 <https://registeredpreventad.loris.ca/> and <https://www.mcgill.ca/bic/neuroinformatics/omega>)³². The
26 remaining data can be shared upon approval by the scientific committee at the Centre for Studies on
27 Prevention of Alzheimer's Disease (StoP-AD) at the Douglas Mental Health University Institute.

28 Normative neurotransmitter density data are available from *neuromaps*
29 (<https://github.com/netneurolab/neuromaps>).

1 Acknowledgements

2 We would like to acknowledge the efforts of our research participants, and thank them for their selflessness
3 and kind demeanour. We would also like to thank the research and clinical staff who conducted patient
4 recruitment and data collection for this study.

5 This work was supported to AIW by a Banting Postdoctoral Fellowship from the Canadian Institutes of
6 Health Research (CIHR; BPF-186555) and grant F32-NS119375 from the United States National Institutes of
7 Health (NIH); to JGR from the Mexican National Council of Science and Technology (CONACyT; 2020-
8 000017-02EXTF-00402) and the Healthy Brains Healthy Lives program at McGill University; to SV from the
9 Alzheimer Society of Canada, the Alzheimer Association, the Canadian Institutes of Health Research (CIHR,
10 438655), and a CIHR Canada Research Chair Tier 2 and a Brain Canada Platform grant; to SB from a NSERC
11 Discovery grant (RGPIN-2020-06889), the CIHR Canada Research Chair (Tier 1; CRC-2017-00311) of Neural
12 Dynamics of Brain Systems, a grant from the NIH (R01-EB026299), and by the Canada Brain Research Fund
13 (CBRF), an innovative arrangement between the Government of Canada (through Health Canada) and Brain
14 Canada Foundation, and Alzheimer's Association; and to TWW from the NIH (R01-MH116782-S1; R01-
15 MH118013-S1). The funders had no role in study design, data collection and analysis, decision to publish,
16 or preparation of the manuscript.

17 PREVENT-AD was launched in 2011 as a \$13.5 million, 7-year public-private partnership using funds
18 provided by McGill University, the FRQS, an unrestricted research grant from Pfizer Canada, the Levesque
19 Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the
20 Canada Fund for Innovation. Private sector contributions are facilitated by the Development Office of the
21 McGill University Faculty of Medicine and by the Douglas Hospital Research Centre Foundation
22 (<http://www.douglas.qc.ca/>).

23 Author Contributions

24 AIW, SV, SB and TWW contributed to the conception and design of the study; AIW and JGR contributed to
25 the analysis of the data; and AIW contributed to drafting the text and preparing the figures. All authors
26 contributed to editing of the manuscript.

27 Potential Conflicts of Interest

28 The authors report no conflicts of interest.

References

- 1 Wiesman, A. I. *et al.* Spatially resolved neural slowing predicts impairment and amyloid burden in Alzheimer's disease. *Brain* **145**, 2177-2189 (2022). <https://doi.org/10.1093/brain/awab430>
- 2 Ranasinghe, K. G. *et al.* Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid- β accumulation, and cognitive decline. *Science translational medicine* **12** (2020).
- 3 Ranasinghe, K. G. *et al.* Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease. *Alzheimer's & Dementia* (2021).
- 4 Nakamura, A. *et al.* Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. *Brain* **141**, 1470-1485 (2018).
- 5 Wiesman, A. I. *et al.* Spatio-spectral relationships between pathological neural dynamics and cognitive impairment along the Alzheimer's disease spectrum. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* **13**, e12200 (2021).
- 6 Osipova, D., Ahveninen, J., Jensen, O., Ylikoski, A. & Pekkonen, E. Altered generation of spontaneous oscillations in Alzheimer's disease. *Neuroimage* **27**, 835-841 (2005). <https://doi.org/10.1016/j.neuroimage.2005.05.011>
- 7 Engels, M. *et al.* Alzheimer's disease: the state of the art in resting-state magnetoencephalography. *Clinical Neurophysiology* **128**, 1426-1437 (2017).
- 8 Fernández, A. *et al.* Focal temporoparietal slow activity in Alzheimer's disease revealed by magnetoencephalography. *Biological psychiatry* **52**, 764-770 (2002).
- 9 Berendse, H., Verbunt, J., Scheltens, P., Van Dijk, B. & Jonkman, E. Magnetoencephalographic analysis of cortical activity in Alzheimer's disease: a pilot study. *Clinical Neurophysiology* **111**, 604-612 (2000).
- 10 Fernández, A. *et al.* MEG spectral profile in Alzheimer's disease and mild cognitive impairment. *Clinical Neurophysiology* **117**, 306-314 (2006).
- 11 de Haan, W. *et al.* Resting-state oscillatory brain dynamics in Alzheimer disease. *Journal of Clinical Neurophysiology* **25**, 187-193 (2008).
- 12 López-Sanz, D., Serrano, N. & Maestú, F. The role of magnetoencephalography in the early stages of Alzheimer's disease. *Frontiers in neuroscience* **12**, 572 (2018).
- 13 Mandal, P. K., Banerjee, A., Tripathi, M. & Sharma, A. A comprehensive review of magnetoencephalography (MEG) studies for brain functionality in healthy aging and Alzheimer's disease (AD). *Frontiers in Computational Neuroscience* **12**, 60 (2018).
- 14 Wiesman, A. I. *et al.* Adverse and compensatory neurophysiological slowing in Parkinson's disease. *Progress in Neurobiology*, 102538 (2023).
- 15 Kopčanová, M. *et al.* Resting-state EEG signatures of Alzheimer's disease are driven by periodic but not aperiodic changes. *Neurobiology of Disease*, 106380 (2023).
- 16 Helfrich, R. F. *et al.* Entrainment of brain oscillations by transcranial alternating current stimulation. *Curr Biol* **24**, 333-339 (2014). <https://doi.org/10.1016/j.cub.2013.12.041>
- 17 Calderone, D. J., Lakatos, P., Butler, P. D. & Castellanos, F. X. Entrainment of neural oscillations as a modifiable substrate of attention. *Trends Cogn Sci* **18**, 300-309 (2014). <https://doi.org/10.1016/j.tics.2014.02.005>
- 18 Wiesman, A. I., Groff, B. R. & Wilson, T. W. Frontoparietal Networks Mediate the Behavioral Impact of Alpha Inhibition in Visual Cortex. *Cereb Cortex* (2018). <https://doi.org/10.1093/cercor/bhy220>
- 19 Wiesman, A. I. & Wilson, T. W. Alpha Frequency Entrainment Reduces the Effect of Visual Distractors. *Journal of cognitive neuroscience*, 1-12 (2019).
- 20 Coffey, E. B., Herholz, S. C., Chepesiuk, A. M., Baillet, S. & Zatorre, R. J. Cortical contributions to the auditory frequency-following response revealed by MEG. *Nature communications* **7**, 1-11 (2016).
- 21 Albouy, P., Weiss, A., Baillet, S. & Zatorre, R. J. Selective entrainment of theta oscillations in the dorsal stream causally enhances auditory working memory performance. *Neuron* **94**, 193-206. e195 (2017).
- 22 Marucci, G. *et al.* Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. *Neuropharmacology* **190**, 108352 (2021).
- 23 Yi, J. H. *et al.* M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer's disease pathology. *Brain Communications* **2**, fcaa058 (2020).

- 24 Dwomoh, L., Tejada, G. S. & Tobin, A. B. Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease. *Neuronal Signaling* **6**, NS20210004 (2022).
- 25 Bukke, V. N. *et al.* The dual role of glutamatergic neurotransmission in Alzheimer's disease: from pathophysiology to pharmacotherapy. *International journal of molecular sciences* **21**, 7452 (2020).
- 26 Mdawar, B., Ghossoub, E. & Khoury, R. Selective serotonin reuptake inhibitors and Alzheimer's disease. *Neural regeneration research* **15**, 41 (2020).
- 27 Chakraborty, S. *et al.* Serotonergic system, cognition, and BPSD in Alzheimer's disease. *Neuroscience letters* **704**, 36-44 (2019).
- 28 Mitchell, R. A., Herrmann, N. & Lanctôt, K. L. The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. *CNS neuroscience & therapeutics* **17**, 411-427 (2011).
- 29 Martorana, A. & Koch, G. Is dopamine involved in Alzheimer's disease? *Frontiers in aging neuroscience* **6**, 252 (2014).
- 30 Wiesman, A. I. *et al.* Alterations of cortical structure and neurophysiology in Parkinson's disease are aligned with neurochemical systems. *Annals of Neurology* (2023).
- 31 McKhann, G. M. *et al.* The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia* **7**, 263-269 (2011).
- 32 Tremblay-Mercier, J. *et al.* Open Science Datasets from PREVENT-AD, a Longitudinal Cohort of Pre-symptomatic Alzheimer's Disease. *NeuroImage: Clinical*, 102733 (2021).
- 33 Wechsler, D. Advanced clinical solutions for the WAIS-IV and WMS-IV. *San Antonio, TX: The Psychological Corporation* (2009).
- 34 Heaton, R., Miller, S. W., Taylor, M. J. & Grant, I. Revised comprehensive norms for an expanded Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults. *Lutz, FL: Psychological Assessment Resources* (2004).
- 35 Wechsler, D. Wechsler adult intelligence scale—Fourth Edition (WAIS—IV). *San Antonio, TX: NCS Pearson* **22**, 1 (2008).
- 36 Brandt, J. & Benedict, R. H. *Hopkins verbal learning test—revised: professional manual.* (Psychological Assessment Resources, 2001).
- 37 Wiesman, A. I. *et al.* Somatosensory dysfunction is masked by variable cognitive deficits across patients on the Alzheimer's disease spectrum. *EBioMedicine* **73**, 103638 (2021).
- 38 Wiesman, A. I. *et al.* Spatially resolved neural slowing predicts impairment and amyloid burden in Alzheimer's disease. *Brain* (2022). <https://doi.org/10.1093/brain/awab430>
- 39 Pfeffer, R. I., Kurosaki, T. T., Harrah Jr, C., Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. *Journal of gerontology* **37**, 323-329 (1982).
- 40 Galvin, J. E. The Quick Dementia Rating System (QDRS): a rapid dementia staging tool. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* **1**, 249-259 (2015).
- 41 Nasreddine, Z. S. *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* **53**, 695-699 (2005). <https://doi.org/10.1111/j.1532-5415.2005.53221.x>
- 42 Folstein, M. F., Folstein, S. E. & McHugh, P. R. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. *Journal of psychiatric research* **12**, 189-198 (1975).
- 43 Randolph, C., Tierney, M. C., Mohr, E. & Chase, T. N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. *Journal of clinical and experimental neuropsychology* **20**, 310-319 (1998).
- 44 Weintraub, S., Wicklund, A. H. & Salmon, D. P. The neuropsychological profile of Alzheimer disease. *Cold Spring Harbor perspectives in medicine* **2**, a006171 (2012).
- 45 Minoshima, S. *et al.* SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. *Journal of Nuclear Medicine* **57**, 1316-1322 (2016).
- 46 Joshi, A. D. *et al.* Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. *Journal of Nuclear Medicine* **53**, 378-384 (2012).
- 47 Diedrichsen, J. A spatially unbiased atlas template of the human cerebellum. *Neuroimage* **33**, 127-138 (2006).
- 48 Jack Jr, C. R. *et al.* Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimer's & Dementia* **13**, 205-216 (2017).
- 49 Fischl, B. FreeSurfer. *Neuroimage* **62**, 774-781 (2012).

- 50 Guo, T., Landau, S. M., Jagust, W. J. & Initiative, A. s. D. N. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. *Neurology* **94**, e1512-e1524 (2020).
- 51 Landau, S. M. *et al.* Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Annals of neurology* **72**, 578-586 (2012).
- 52 Desikan, R. S. *et al.* An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage* **31**, 968-980 (2006).
- 53 Sibomana, M., Keller, S. H., Stute, S. & Comtat, C. in 2012 IEEE Nuclear Science Symposium and Medical Imaging Conference Record (NSS/MIC). 2954-2957 (IEEE).
- 54 Jack Jr, C. R. *et al.* Predicting amyloid PET and tau PET stages with plasma biomarkers. *Brain* **146**, 2029-2044 (2023).
- 55 Klunk, W. E. *et al.* The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimer's & dementia* **11**, 1-15. e14 (2015).
- 56 Rowe, C. C. *et al.* Standardized expression of 18F-NAV4694 and 11C-PIB β -amyloid PET results with the Centiloid scale. *Journal of Nuclear Medicine* **57**, 1233-1237 (2016).
- 57 Farrell, M. E. *et al.* Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. *Neurology* **96**, e619-e631 (2021).
- 58 Farrell, M. E. *et al.* Association of emerging β -amyloid and tau pathology with early cognitive changes in clinically normal older adults. *Neurology* **98**, e1512-e1524 (2022).
- 59 Wiesman, A. I., da Silva Castanheira, J. & Baillet, S. Stability of spectral estimates in resting-state magnetoencephalography: Recommendations for minimal data duration with neuroanatomical specificity. *Neuroimage* **247**, 118823 (2022). <https://doi.org/10.1016/j.neuroimage.2021.118823>
- 60 Taulu, S. & Simola, J. Spatiotemporal signal space separation method for rejecting nearby interference in MEG measurements. *Phys Med Biol* **51**, 1759-1768 (2006). <https://doi.org/10.1088/0031-9155/51/7/008>
- 61 Tadel, F., Baillet, S., Mosher, J. C., Pantazis, D. & Leahy, R. M. Brainstorm: a user-friendly application for MEG/EEG analysis. *Computational intelligence and neuroscience* **2011** (2011).
- 62 Gross, J. *et al.* Good practice for conducting and reporting MEG research. *Neuroimage* **65**, 349-363 (2013).
- 63 Baillet, S. Magnetoencephalography for brain electrophysiology and imaging. *Nature neuroscience* **20**, 327 (2017).
- 64 Donoghue, T. *et al.* Parameterizing neural power spectra into periodic and aperiodic components. *Nature neuroscience* **23**, 1655-1665 (2020).
- 65 Markello, R. D. *et al.* Neuromaps: structural and functional interpretation of brain maps. *BioRxiv* (2022).
- 66 Hansen, J. Y. *et al.* Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. *Nature Neuroscience* (2022). <https://doi.org/10.1038/s41593-022-01186-3>
- 67 Camargo, A. PCAtest: testing the statistical significance of Principal Component Analysis in R. *PeerJ* **10**, e12967 (2022).
- 68 Team, R. C. (R Foundation for Statistical Computing, Vienna, Austria, 2017).
- 69 Baron, R. M. & Kenny, D. A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol* **51**, 1173-1182 (1986).
- 70 Tingley, D., Yamamoto, T., Hirose, K., Keele, L. & Imai, K. mediation: R Package for Causal Mediation Analysis. *Journal of Statistical Software* **59**, 1-38 (2014).
- 71 Volpicelli, L. A. & Levey, A. I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. *Progress in brain research* **145**, 59-66 (2004).
- 72 Lebois, E., Thorn, C., Edgerton, J., Popielek, M. & Xi, S. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease. *Neuropharmacology* **136**, 362-373 (2018).
- 73 Davis, A. A., Fritz, J. J., Wess, J., Lah, J. J. & Levey, A. I. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. *Journal of Neuroscience* **30**, 4190-4196 (2010).
- 74 Jones, C. K. *et al.* Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. *Journal of Neuroscience* **28**, 10422-10433 (2008).
- 75 Beach, T. G., Walker, D. G., Potter, P. E., Sue, L. I. & Fisher, A. Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists. *Brain research* **905**, 220-223 (2001).
- 76 Jafari, Z., Kolb, B. E. & Mohajerani, M. H. Neural oscillations and brain stimulation in Alzheimer's disease. *Progress in neurobiology* **194**, 101878 (2020).

- 77 Yin, W. *et al.* Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. *British Journal of Clinical Pharmacology* **88**, 600-612 (2022).
- 78 Ebert & Kirch. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. *European journal of clinical investigation* **28**, 944-949 (1998).
- 79 Montani, C. *et al.* The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. *Neuropsychopharmacology* **46**, 1194-1206 (2021).
- 80 Thienel, R. *et al.* Muscarinic antagonist effects on executive control of attention. *International Journal of Neuropsychopharmacology* **12**, 1307-1317 (2009).
- 81 Herrero, J. L. *et al.* Acetylcholine contributes through muscarinic receptors to attentional modulation in V1. *Nature* **454**, 1110-1114 (2008).
- 82 Ellis, J. R. *et al.* Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. *International Journal of Neuropsychopharmacology* **9**, 175-189 (2006).
- 83 Medeiros, R. *et al.* Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. *The American journal of pathology* **179**, 980-991 (2011).
- 84 Lopez, O. L. *et al.* Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. *Neurology* **41**, 906-906 (1991).
- 85 Dauwan, M. *et al.* EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies. *Neurobiology of aging* **67**, 75-83 (2018).
- 86 Liu, F., Fuh, J.-L., Peng, C.-K. & Yang, A. C. Phenotyping neuropsychiatric symptoms profiles of Alzheimer's disease using cluster analysis on EEG power. *Frontiers in Aging Neuroscience* **13**, 623930 (2021).
- 87 Chen, C.-W. *et al.* Reduced slow-wave activity and autonomic dysfunction during sleep precede cognitive deficits in Alzheimer's disease transgenic mice. *Scientific reports* **13**, 11231 (2023).
- 88 Mega, M. S., Cummings, J. L., Fiorello, T. & Gornbein, J. The spectrum of behavioral changes in Alzheimer's disease. *Neurology* **46**, 130-135 (1996).
- 89 Van der Musselle, S. *et al.* Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. *International journal of geriatric psychiatry* **28**, 265-275 (2013).
- 90 Rajmohan, R. & Reddy, P. H. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons. *Journal of Alzheimer's Disease* **57**, 975-999 (2017).
- 91 Bell, K. F. *et al.* The amyloid pathology progresses in a neurotransmitter-specific manner. *Neurobiology of aging* **27**, 1644-1657 (2006).
- 92 Weiner, M. W. *et al.* The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. *Alzheimer's & Dementia* **9**, e111-e194 (2013).

Figure Captions

Figure 1. Topographies of normative neurochemical gradients and neurophysiological alterations in patients with aMCI and AD. Normative gradients of cortical neurotransmitter system density were derived from 19 normative neurotransmitter atlases using principal component analysis. The first four principal components (pc1 to pc4) explained more than 80% of the variance across atlases (all p 's < .001; 1,000 permutations). Heatmaps in (a) show the respective loadings (i.e., eigenvectors) for each neurochemical gradient across the 19 atlases. Positive and negative loadings are colored red and blue, respectively, and labels in black indicate systems that significantly contribute to each gradient (p 's < .05; 1,000 permutations). The spatial topographies of these neurochemical gradients are shown as cortical maps in (b), with warm colors indicating regions with high densities of positively-loaded neurochemical systems and cool colors indicating regions with high densities of negatively-loaded systems. The cortical maps shown in (c) indicate the group-average spatial topographies of alterations in rhythmic neurophysiology in patients with aMCI and AD from the DMAP cohort, per each canonical frequency band (i.e., δ : 2 – 4 Hz; θ : 5 – 7 Hz; α : 8 – 12 Hz; β : 15 – 29 Hz). Note that these topographies represent rhythmic neurophysiological measures that have been standardized (i.e., z-scored) to the comparable data from the healthy control participants. Warm and cool colors indicate increases and decreases in rhythmic activity relative to healthy levels, respectively.

Figure 2. Neurophysiological alterations in patients with aMCI and AD align to neurochemical systems with relevance for clinical symptoms. The heatmap in (a) indicates the strength of the alignments between band-limited alterations in rhythmic neurophysiology (y-axis) and the normative neurochemical gradients (x-axis) from Figure 1. Colors indicate the t-values of these relationships, with asterisks indicating statistical significance after correcting for multiple comparisons. Line plots in (a) show the participant-level simple slopes representing two of these alignments, with the remaining alignments displayed in Figure S2. Overlaid cortical maps indicate the dot product of the relevant neurophysiological alterations and neurochemical gradient densities per region, with warm and cool colors indicating positive and negative agreement, respectively, between the two measures. Representative topographies of delta rhythmic alterations from patients with high and low alignment to the second neurochemical gradient are shown in Figure S3. Scatterplots in (b) indicate the moderations of neurochemical-neurophysiological alignments from (a) by cross-sectional clinical symptom severity, with the strength of alignment shown on the x-axis and the clinical symptom score shown on the y-axis. Inlaid neurotransmitter receptor/transporter abbreviations indicate the respective atlases that replicate the relevant moderation effect in post-hoc testing, with the color and saturation of each label indicating the sign of the corresponding loading onto the neurochemical gradient. For all plots, the color of the lines/points indicates whether patients were in the amnesic mild cognitive impairment or probable Alzheimer's disease clinical subgroup. *** $p_{FDR} < .005$, ** $p_{FDR} < .01$, * $p_{FDR} < .05$.

Figure 3. Cortical deposition of amyloid- β in patients with aMCI and AD aligns with neurochemical systems. Cortical maps in (a) show the mean topography of amyloid- β deposition (in standardized uptake value ratios; derived from ^{18}F florbetapir positron emission tomography) across patients with aMCI and AD from the DMAP cohort. The heatmap in (b) indicates the strength of the alignments between cortical deposition of amyloid- β (x-axis) and the normative neurochemical gradients (y-axis) in these patients. Colors indicate the t-values of these relationships, with asterisks indicating statistical significance after correcting for multiple comparisons. Line plots in (b) show the participant-level simple slopes representing the alignments from (a), with line color indicating whether patients were in the amnesic mild cognitive impairment or

probable Alzheimer's disease clinical subgroup. Cortical maps below are the dot product of the amyloid- β values and neurochemical gradient densities per region, with warm and cool colors indicating positive and negative agreement, respectively, between the two measures. Representative topographies of amyloid- β deposition from patients with high and low alignment to the fourth neurochemical gradient are shown in Figure S4. *** $p_{\text{FDR}} < .005$.

Figure 4. Amyloid- β deposition mediates the neurochemical alignment of beta rhythmic alterations in patients with aMCI and AD. Cortical maps indicate the topographies of mean beta rhythmic alterations (bottom left), mean amyloid- β deposition (top), and the fourth normative neurochemical gradient (bottom right). Linear mixed-effects model statistics (t -values) above the paths between these variables indicate their alignment, with asterisks representing statistical significance. The t -value below the path on the bottom indicates the residual alignment of beta rhythmic alterations with the fourth neurochemical gradient when amyloid- β deposition is included in the model. The average causal mediation effect (ACME) is shown at the top, confirming an indirect effect. This indirect effect was also significant when the fourth neurochemical gradient was replaced with the atlas of muscarinic acetylcholine M1 receptor densities. *** $p_{\text{FDR}} < .005$, ** $p_{\text{FDR}} < .01$, * $p_{\text{FDR}} < .05$.

Figure 5. Alignments between normative neurochemical gradients, neurophysiological alterations, and proteinopathy are detectable in the asymptomatic stages of A β deposition. The rhythmic neurophysiological measures from the high-A β individuals ($N = 33$) from the PREVENT-AD cohort were standardized to the comparable data from the low-A β individuals ($N = 71$) to generate the neurophysiological alteration maps shown in (a). The heatmap in (b) indicates the replication in PREVENT-AD high A β participants of neurochemical-neurophysiological alignments that were observed in patients with aMCI and AD from the DMAP cohort, with band-limited alterations in rhythmic neurophysiology on the y-axis and normative neurochemical atlases on the x-axis. The colors of the squares indicate the t -values of these alignments, with asterisks indicating statistical significance after correcting for multiple comparisons. Grey squares were not significant in the DMAP cohort, and were not examined. Brain maps in (c) indicate the mean topography of A β deposition (in standardized uptake value ratios; derived from ^{18}F NAV4694 positron emission tomography) across asymptomatic adults with high A β deposition from the PREVENT-AD cohort. The heatmap in (c) indicates the replication in PREVENT-AD high A β participants of neurochemical-A β alignments that were observed in patients with aMCI and AD from the DMAP cohort. Similar to (b), colors indicate the t -values of these relationships, with asterisks indicating statistical significance after correcting for multiple comparisons. *** $p_{\text{FDR}} < .005$, ** $p_{\text{FDR}} < .01$, * $p_{\text{FDR}} < .05$.

Table 1. Group demographics and comparisons.

Group	Age (mean years)	Sex (% female)	Education (mean years)
DMAP			
aMCI/AD (N = 38)	69.21 (6.91)	47.37	15.50 (2.72)
HC (N = 20)	72.70 (4.73)*	60.00	16.60 (2.87)
PREVENT-AD			
High-A β (N = 33)	67.66 (5.17)	78.79*	14.64 (2.70)
Low-A β (N = 71)	67.28 (4.83)	67.61	15.25 (3.31)

DMAP: Dynamic Mapping of Alzheimer's disease Pathology study; aMCI: amnesic mild cognitive impairment; AD: Alzheimer's disease; HC: healthy control; PREVENT-AD: Pre-symptomatic Evaluation of Novel or Experimental Treatments for Alzheimer's Disease study; A β : amyloid- β . Parentheticals for continuous variables indicate one standard deviation. * $p < .05$, compared to the aMCI/AD group.